153 results
6-K
EX-99.3
SNY
Sanofi
28 May 24
Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
12:04pm
a first-of-its-kind medical advancement for the COPD community.”
As presented and published, the NOTUS study met its primary and key secondary
6-K
EX-99.4
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
Hospitalizations Among Young Children: 2015-2016. Pediatrics. 2020;146:e20193611.
Arriola CS, et al. Estimated Burden of Community-Onset Respiratory Syncytial
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
of care within the church health institutions participating in the project. It includes building the capacity of health workers and community
F-3ASR
EX-25.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
Percentage
31. Leverage ratio (item 26 divided by item 30)
26.6492%
a. Does your institution have a community bank leverage ratio (CBLR) framework
6-K
EX-99.1
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
for frexalimab represent important data in not only the potential treatment of MS but to the broader MS community. Of note, at Week 12, both doses
6-K
EX-99.1
apyzcn l77
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.5
awelu91thn04bafqs23
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
jifq5o4vo4b
27 Oct 23
Sanofi Enters Next Chapter of Play to Win Strategy
11:33am
6-K
EX-99.3
9ivxqv 1887ve
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.2
ot8 rkhj9zbetjo74
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.1
roauv2
27 Sep 23
Current report (foreign)
6:06am
6-K
EX-99.1
rx48d sd6
10 Aug 23
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
9:50am
6-K
EX-99.1
vv0id
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
EX-99.2
85g58rydks5 to
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
ku8ai1r8wmbwpwirzuf
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.2
8s9end v2
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.3
mlan9i7k 7ait
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.1
idhqrqqjv9e
23 May 23
Current report (foreign)
1:01pm
6-K
EX-99.1
l5t613wszv9 wycjna
10 Nov 22
European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
2:00pm
6-K
EX-99.1
7zneux 520135q
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am